Long-term safety follow-up of people who received a Caribou cell therapy for lymphoma
Follows adults with non-Hodgkin lymphoma who previously received a Caribou investigational cell therapy.
Plain-language title generated from the registry record
Registry title: Long-Term Follow-up Study
Key facts
- Where
- Atlanta, Augusta, Birmingham, Charlotte, Cincinnati, Cleveland, Dallas, Denver, Gilbert, Hackensack, Houston, Iowa City, Irvine, La Jolla, Lexington, Louisville, Miami, Milwaukee, Morristown, Nashville, New York, Orlando, Philadelphia, Richmond, Salt Lake City, Scottsdale, Seattle, and The Bronx, United StatesSee the 31 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who already received a Caribou cell therapy in an earlier Caribou study, special access program or investigator-initiated study. It follows their long-term safety through 15 years after the infusion.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Earlier treatment
- Must have completed a Caribou-sponsored study, or have been given a Caribou investigational product under a special access program or an investigator-initiated study.
Main reasons for not taking part
- The record lists no exclusion criteria.
Read by machine on 9 November 2026.
Where in United States
- Blood & Marrow Transplant Group of GeorgiaAtlanta, United StatesNo longer taking part
- Augusta University, Georgia Cancer CenterAugusta, United StatesNo longer taking part
- University of AlabamaBirmingham, United StatesNo longer taking part
- Levine Cancer CenterCharlotte, United StatesNo longer taking part
- Oncology Hematology CareCincinnati, United StatesNo longer taking part
- Cleveland ClinicCleveland, United StatesNo longer taking part
- Baylor Research InstituteDallas, United StatesNo longer taking part
- University of Texas, SouthwesternDallas, United StatesNo longer taking part
- Colorado Blood Cancer InstituteDenver, United StatesNo longer taking part
- University of ColoradoDenver, United StatesNo longer taking part
- Banner MD Anderson Cancer CenterGilbert, United StatesNo longer taking part
- Regional Cancer Care Associates - HackensackHackensack, United StatesNo longer taking part
- MD Anderson Cancer CenterHouston, United StatesNo longer taking part
- University of Iowa Hospitals & ClinicsIowa City, United StatesNo longer taking part
- University of California, IrvineIrvine, United StatesNo longer taking part
- University of California San DiegoLa Jolla, United StatesNo longer taking part
- University of KentuckyLexington, United StatesNo longer taking part
- Norton Cancer InstituteLouisville, United StatesNo longer taking part
- University of MiamiMiami, United StatesNo longer taking part
- Medical College of WisconsinMilwaukee, United StatesNo longer taking part
- Atlantic Health System Cancer CareMorristown, United StatesNo longer taking part
- Sarah Cannon Research Institute - TriStar HealthNashville, United StatesNo longer taking part
- Icahn School of Medicine at Mt. SinaiNew York, United StatesNo longer taking part
- Weill Cornell MedicineNew York, United StatesNo longer taking part
- AdventHealth Medical Group Blood & Marrow Transplant at OrlandoOrlando, United StatesNo longer taking part
- University of PennsylvaniaPhiladelphia, United StatesNo longer taking part
- Virginia Commonwealth UniversityRichmond, United StatesNo longer taking part
- Huntsman Cancer Institute at the University of UtahSalt Lake City, United StatesNo longer taking part
- Honor Health Research InstituteScottsdale, United StatesNo longer taking part
- Fred Hutchinson Cancer CenterSeattle, United StatesNo longer taking part
- Montefiore Medical CenterThe Bronx, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Caribou Biosciences, Inc.
- Trial code
- NCT05332054
- Record updated
- 12 March 2026
- Original description
This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT. The objective is to evaluate the long-term safety, through 15 years post infusion, in patients who received IPs in a Caribou-sponsored clinical study, special access program or IIT.Read full original descriptionShow less
An Observational Long-Term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy
This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT. The objective is to evaluate the long-term safety, through 15 years post infusion, in patients who received IPs in a Caribou-sponsored clinical study, special access program or IIT.
Inclusion: Written informed consent (by patient or legal representative) obtained prior to study-specific activities/enrollment; Completed a Caribou-sponsored study or was administered Caribou IP under a special access program or as part of an IIT; Use of an effective method of birth control by women of childbearing potential and their partners and men with partners of childbearing potential (partners must also use an effective birth control method) through 12 months post IP infusion.
Exclusion: None.